Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

MediSieve in the news

MediSieve in the news
Created on 6/15/2018 6:07:52 PM

You may have seen our recent announcement that MediSieve has received over £1.75 million in funding...
Ground-breaking medical blood treatment passes £1.75 million in funding

Ground-breaking medical blood treatment passes £1.75 million in funding
Created on 6/4/2018 10:53:54 AM

MediSieve Ltd, the team behind an innovative blood filtration device, are happy to announce the com...